Avancerad sökning
Visar resultat 1 - 5 av 42 avhandlingar som matchar ovanstående sökkriterier.
1. The regulation of factor Va activity by activated protein C -Importance of the individual activated protein C cleavage sites in factor Va
Sammanfattning : The subject of this thesis is the activated protein C (APC)-mediated inactivation of factor Va. The activated form of factor V (FVa) is a procoagulant cofactor for Factor Xa (FXa) in the conversion of prothrombin to thrombin. LÄS MER
2. Resistance to activated protein C a novel risk factor for venous thrombosis
Sammanfattning : Activated protein C resistance (APC resistance) is the most common hereditary condition associated with venous thrombosis. The syndrome known as APC resistance is perfectly linked to a mutation in the gene coding coagulation FV (FV:Q506) mutation changing Arg 506 to Gln in the APC cleavage site. LÄS MER
3. Pro- and anticoagulant mechanisms in coronary artery disease. Clinical studies on factor VII and resistance to activated protein C
Sammanfattning : The triggering mechanism in myocardial infarction (MI) and unstable angina involves coronary thrombus formation following plaque rupture. Coagulation is initiated by tissue factor that activates factor VII (FVII), and is inhibited by protein C and its co-factor protein S. LÄS MER
4. Familial thrombophilia : Resistance to activated protein C and protein S deficiency
Sammanfattning : Inherited resistance to activated protein C (APC-resistance) and protein S deficiency are associated with functional impairment of the protein C anticoagulant system, resulting in lifelong hypercoagulability andincreased risk of thrombosis. APC-resistance is the most common genetic cause of thrombosis being present in 20% to 60% of thrombosis patients. LÄS MER
5. Arterial Thrombosis in Factor V Leiden or Activated Protein C Resistance. Clinical and Experimental Studies
Sammanfattning : Abstract The last two decades has seen an avalanche of studies establishing Activated protein C (APC) resistance due to Factor V Leiden mutation as the most prevalent genetic risk factor, yet known, for venous thromboembolism. This has been documented in 20-60% of patients with deep vein thrombosis (DVT). LÄS MER